CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results

SAN DIEGO, CA / ACCESS Newswire / March 26, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the year and quarter ended December 31, 2025. Fiscal 2025, Fourth Quarter 2025 and Recent Financial and Operating Highlights Generated revenue of $13.8 million for fiscal 2025 compared to $15.7 million for 2024; Revenue of $3.3 million for the fourth quarter 2025 compared to $3.9 million for the fourth quarter 2024 and $3.3 million for the third quarter 2025; Recognized gross margin of 49.0% for fiscal 2025, a significant improvement from 45.6% for 2024; Gross margin of 50.5% for the fourth quarter 2025 compared to 43.2% for the fourth quarter 2024 and 48.5% for the third quarter 2025; Cash balance of $0.3 million at year end compared to $0.5 million at the end of 2024; Reduced operating expenses by 17.2% to $7.7 million for fiscal 2025 compared to $9.4 million for 2024, excluding benefit from reversal of accrued payroll taxes; Recognized an adjusted EBITDA loss of $0.3 million for fiscal 2025 compared to $0.8 million for 2024; Recognized positive adjusted EBITDA of $0.1 million for the fourth quarter 2025, significantly improved from adjusted EBITDA losses of $0.4 million for the fourth quarter 2024 and $0.1 million for the third quarter 2025; Expanded +PlusCBD™ product offering with the launch of Ignite, a men's performance formula for vitality, recovery, libido and focus (Q3 2025); and Launched EMPOWR, a plant-based protein and creatine formula designed for total wellness (Q1 2026), and Completed successful debt restructuring designed to strengthen financial position and fuel future growth (Q1 2026).